论文部分内容阅读
目的观察维格列汀对2型糖尿病合并冠心病患者血清脂联素、抵抗素水平的影响。方法将60例冠心病合并糖尿病患者随机分为2组,观察组给予维格列汀口服治疗,对照组给予二甲双胍口服治疗,2组均治疗10周。检测2组治疗前后血清脂联素(APN)、抵抗素(RET)、肿瘤坏死因子-α(TNF-α)、空腹血糖(FBG)和胰岛素(FINS)、总胆固醇(TC)、三酰甘油(TG)、游离脂肪酸(FFA)水平,计算胰岛素敏感指数(ISI)和胰岛素抵抗指数(HOMA-IR)。结果治疗后对照组FBG、APN、RET、FFA均较治疗前明显改善(P均<0.05);观察组除TC、TG无明显变化外,其余指标均较治疗前明显改善(P均<0.05),且观察组改善情况明显优于对照组(P均<0.05)。结论维格列汀能有效降低2型糖尿病合并冠心病患者血清RET水平,提高APN水平,改善胰岛素抵抗。
Objective To observe the effect of vildagliptin on serum adiponectin and resistin in type 2 diabetic patients with coronary heart disease. Methods Sixty coronary heart disease patients with diabetes mellitus were randomly divided into two groups: the observation group received oral vildagliptin, the control group received metformin oral treatment, and the other two groups were treated for 10 weeks. The levels of serum adiponectin (APN), resistin (RET), tumor necrosis factor-α (TNF-α), fasting blood glucose (FBG) and insulin (FINS), total cholesterol (TC), triglyceride (TG), free fatty acid (FFA), insulin sensitivity index (ISI) and insulin resistance index (HOMA-IR) were calculated. Results After treatment, the FBG, APN, RET and FFA in the control group were significantly improved compared with those before treatment (all P <0.05). The indexes in the observation group were significantly improved except TC and TG (P <0.05) , And the observation group improved significantly better than the control group (P all <0.05). Conclusion Vildagliptin can effectively reduce serum RET level, improve APN level and improve insulin resistance in type 2 diabetic patients with coronary heart disease.